Ascendis Pharma Faces Revenue Shortfall, Pipeline Advances Temper Outlook
核心洞察
Ascendis Pharma's Skytrofa revenue missed estimates due to increased sales deductions, leading to a downward revision of FY24 revenue guidance.
Upcoming milestones include Phase 2 data for Turner syndrome (搜索) and the initiation of a basket study for other growth hormone indications in 2025.
Regulatory submissions for Ascendis Pharma's C-Type Natriuretic Peptide (CNP) product are on track, with Phase 3 data appearing competitive.
Ascendis Pharma (ASND) is navigating a complex landscape of revenue challenges and promising pipeline developments. Recent financial results revealed that Skytrofa's revenue fell short of expectations, impacting the company's overall outlook, while advancements in its clinical programs and strategic collaborations offer potential for future growth.
Skytrofa Revenue Disappoints
Skytrofa, Ascendis Pharma's growth hormone therapy, generated €47 million in revenue, below TD Cowen's estimate of €55 million and the consensus of €61 million. This shortfall was attributed to increased sales deductions. Consequently, Ascendis Pharma has revised its full-year 2024 revenue guidance for Skytrofa downwards to €200 million - €220 million.
Pipeline Progress and Upcoming Milestones
Despite the revenue setback, Ascendis Pharma is making strides with its pipeline. Phase 2 data for Skytrofa in Turner syndrome (搜索) is expected in the fourth quarter of 2024. Additionally, the company plans to initiate a basket study for other growth hormone indications in the first half of 2025. These developments could expand the potential applications of Skytrofa and contribute to future revenue growth.
Yorvipath, another key product, generated €8.5 million in revenue, aligning with the consensus estimate of €8 million. The U.S. launch of Yorvipath is anticipated in mid-January, marking an important step in expanding its market presence. Citi analysts highlight the potential for Ascendis Pharma's stock to be driven by the upcoming launch of Yorvipath in 2025, with sales in the European Union picking up momentum.
CNP Regulatory Submissions on Track
Ascendis Pharma is also progressing with regulatory submissions for its C-Type Natriuretic Peptide (CNP) product. The New Drug Application (NDA) and Marketing Authorization Application (MAA) filings are on schedule for the first and third quarters of 2025, respectively. According to analysts, the Phase 3 data for CNP appears competitive and supports a significant opportunity in the market.
Strategic Collaboration with Novo Nordisk
A strategic collaboration with Novo Nordisk is expected to offer long-term upside for Ascendis Pharma. The specifics of this deal were not detailed, but it was presented as a positive development for the company, potentially including a $100 million upfront payment and royalties.
Analyst Outlook
TD Cowen adjusted its price target for Ascendis Pharma to $153 from $160, while maintaining a Buy rating. Citi and Oppenheimer also adjusted their price targets, maintaining a Buy and Outperform rating respectively. These ratings reflect confidence in Ascendis Pharma's long-term potential, despite the current revenue challenges.
Financial Health Considerations
InvestingPro Tips highlight that analysts do not anticipate Ascendis Pharma will be profitable this year, consistent with the reported operating loss and the downward revision of FY24 guidance. Additionally, short-term obligations exceed liquid assets, suggesting potential liquidity challenges as the company continues to invest in its pipeline and product launches. Ascendis Pharma anticipates achieving cash flow breakeven by the end of 2025.